Recent Regulatory 8-K events
Recent 8-Ks about regulator actions, exchange notices, compliance events, and approvals.
-
aTyr Pharma reaches FDA alignment on Phase 3 protocol for efzofitimod in pulmonary sarcoidosis
-
SCWorx faces Nasdaq delisting; seeks panel reconsideration after completing share offering
-
Gossamer Bio submits NDA for seralutinib in PAH; FDA acceptance decision expected later 2026
-
Aditxt delisting from Nasdaq finalized; Form 25 to be filed Sept 2026
-
Brightline Interactive announces 1-for-8 reverse stock split to regain Nasdaq bid price compliance
-
Greenland Technologies regains Nasdaq minimum bid price compliance
-
BioCardia updates FDA Helix pre-submission and PMDA CardiAMP HF Shonin timing
-
Lakeshore Acquisition III transfers listing to Nasdaq Capital Market effective Sept 24
-
CytoSorbents regains Nasdaq bid price compliance; MVLS delisting risk remains
-
SiEnergy reaches Texas rate case settlement for $8.6M revenue increase
-
Labcorp reaffirms 2026-29 outlook and flags CMS PAMA rate cuts
-
Reborn Coffee gets Nasdaq delisting notice for low stockholders' equity
-
FDA grants Fast Track to Quoin's QRX003 for Peeling Skin Syndrome
-
TriSalus receives FDA clearance for TriNav Advance liver embolization device
-
Lucid advances EsoGuard/EsoCheck Medicare coding, payment backing from CMS, AMA, CDC
-
USFS approves Idaho Copper's exploration plan, clearing way for drilling at CuMo
-
FDA tells Compass to run survival trial before BLA for tovecimig; company disagrees
-
FDA lifts clinical hold on Filana's simufilam, enabling Phase 2a trial for TSC-related epilepsy
-
Russian decree places Aptar's subsidiary under temporary external administration
-
BioCardia regains Nasdaq minimum bid price compliance; matter closed
-
Linkhome regains Nasdaq minimum bid price compliance; delisting matter closed
-
USACE publishes Notice of Intent to prepare EIS for Trilogy's Arctic Project
-
InMed receives Nasdaq delisting notice for equity shortfall; merger to cure
-
Moleculin Biotech receives Nasdaq delisting notice; bid price below $1 for 30 days
-
Fusemachines receives Nasdaq delisting notice over bid price below $1.00
-
BeyondSpring receives Nasdaq bid-price delisting notice; 180-day cure window to March 16, 2027
-
Filana Therapeutics receives Nasdaq delisting notice over sub-$1.00 bid price
-
Hyperfine receives Nasdaq delisting notice for bid price below $1
-
TELA Bio faces Nasdaq delisting over bid price; plans hearing and reverse split
-
NextNRG receives Nasdaq delisting notice; plans to appeal after missing bid price deadline
-
Stardust Power receives Nasdaq delisting notice for bid price below $1.00
-
GoPro regains Nasdaq minimum bid price compliance after 10-day rule
-
Fifth Era Acquisition receives Nasdaq deficiency notice for missing 400 total holders
-
Ultragenyx gets FDA standard full approval for FAYUVI, first Sanfilippo type A treatment
-
American Water, Essential Utilities file non-unanimous settlement with PaPUC for merger
-
Faraday Future regains Nasdaq equity compliance; EAI robot sales hit 552 units
-
Aquestive resubmits Anaphylm NDA to FDA; addresses CRL with positive human factor/PK data
-
Battalion Oil regains NYSE American listing compliance ahead of deadline
-
Bone Biologics gets Nasdaq bid-price delisting notice; plans reverse split vote
-
Synergy CHC to be delisted from Nasdaq Sept 18 after chapter 11 bankruptcy
-
Range Capital gets Nasdaq notice for failure to meet 400 total holders
-
K&F Growth Acquisition transfers listing to Nasdaq Capital Market to cure holder deficiency
-
Generation Income Properties gets Nasdaq extension to Nov 18, 2026 for bid price compliance
-
Aldel Financial II receives Nasdaq notice for failing minimum 400 public holders rule
-
Exicure gets Nasdaq extension to Dec 2, 2026 for stockholders' equity compliance
-
FDA reclassifies NRx ketamine ANDA amendment from Major to Minor; goal date Nov 10, 2026
-
West Coast Community Bancorp up-lists to Nasdaq; WCCB starts trading Sept 16